Korea’s Boryung Licenses Hypertension Therapy Kanarb To China’s Harbin Gloria
This article was originally published in PharmAsia News
In its latest deal for the sale of its hypertension Kanarb product outside Korea, Boryung signed a 10-year deal with China from 2018.
You may also be interested in...
SEOUL - Following a similar deal with Mexico-based Stendhal International in January, Boryung Pharmaceutical Co. said it is close to signing marketing agreements for its angiotensin receptor blocker Kanarb (fimasartan) in 12 other Central and South American countries
SEOUL - South Korea's Ministry of Health and Welfare has selected 21 Korean pharmaceutical manufacturers and 17 medical equipment firms to support these companies in the development of globally competitive new drugs, marketing efforts and U.S. FDA approvals needed for their advancement into the U.S. market
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.